<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">34894987</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>02</Month>
        <Day>23</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>02</Month>
        <Day>23</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Electronic">1475-6374</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>37</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Dec</Month>
            </PubDate>
          </JournalIssue>
          <Title>Journal of enzyme inhibition and medicinal chemistry</Title>
          <ISOAbbreviation>J Enzyme Inhib Med Chem</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Mechanism of biotin carboxylase inhibition by ethyl 4-[[2-chloro-5-(phenylcarbamoyl)phenyl]sulphonylamino]benzoate.</ArticleTitle>
        <Pagination>
          <StartPage>100</StartPage>
          <EndPage>108</EndPage>
          <MedlinePgn>100-108</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1080/14756366.2021.1994558</ELocationID>
        <Abstract>
          <AbstractText>The rise of antibacterial-resistant bacteria is a major problem in the United States of America and around the world. Millions of patients are infected with antimicrobial resistant bacteria each year. Novel antibacterial agents are needed to combat the growing and present crisis. Acetyl-CoA carboxylase (ACC), the multi-subunit complex which catalyses the first committed step in fatty acid synthesis, is a validated target for antibacterial agents. However, there are at present, no commercially available antibiotics that target ACC. Ethyl 4-[[2-chloro-5-(phenylcarbamoyl)phenyl]sulfonylamino]benzoate (SABA1) is a compound that has been shown to have antibacterial properties against <i>Pseudomonas aeruginosa</i> and <i>Escherichia coli</i>. SABA1 inhibits biotin carboxylase (BC), the enzyme that catalyses the first half reaction of ACC. SABA1 inhibits BC via an atypical mechanism. It binds in the biotin binding site in the presence of ADP. SABA1 represents a potentially new class of antibiotics that can be used to combat the antibacterial resistance crisis.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Craft</LastName>
            <ForeName>Matthew K</ForeName>
            <Initials>MK</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Biological Sciences, Louisiana State University, Baton Rouge, LA, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Waldrop</LastName>
            <ForeName>Grover L</ForeName>
            <Initials>GL</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Biological Sciences, Louisiana State University, Baton Rouge, LA, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>J Enzyme Inhib Med Chem</MedlineTA>
        <NlmUniqueID>101150203</NlmUniqueID>
        <ISSNLinking>1475-6366</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000900">Anti-Bacterial Agents</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D004791">Enzyme Inhibitors</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 6.3.-</RegistryNumber>
          <NameOfSubstance UI="D019731">Carbon-Nitrogen Ligases</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 6.3.4.14</RegistryNumber>
          <NameOfSubstance UI="C019791">biotin carboxylase</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000900" MajorTopicYN="N">Anti-Bacterial Agents</DescriptorName>
          <QualifierName UI="Q000138" MajorTopicYN="N">chemical synthesis</QualifierName>
          <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019731" MajorTopicYN="N">Carbon-Nitrogen Ligases</DescriptorName>
          <QualifierName UI="Q000037" MajorTopicYN="Y">antagonists &amp; inhibitors</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004305" MajorTopicYN="N">Dose-Response Relationship, Drug</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004791" MajorTopicYN="N">Enzyme Inhibitors</DescriptorName>
          <QualifierName UI="Q000138" MajorTopicYN="N">chemical synthesis</QualifierName>
          <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004926" MajorTopicYN="N">Escherichia coli</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008826" MajorTopicYN="N">Microbial Sensitivity Tests</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015394" MajorTopicYN="N">Molecular Structure</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011550" MajorTopicYN="N">Pseudomonas aeruginosa</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013329" MajorTopicYN="N">Structure-Activity Relationship</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Antibiotics</Keyword>
        <Keyword MajorTopicYN="N">acetyl-CoA carboxylase</Keyword>
        <Keyword MajorTopicYN="N">fatty acid synthesis</Keyword>
        <Keyword MajorTopicYN="N">molecular docking</Keyword>
      </KeywordList>
      <CoiStatement>No potential conflict of interest was reported by the author(s).</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="entrez">
          <Year>2021</Year>
          <Month>12</Month>
          <Day>13</Day>
          <Hour>11</Hour>
          <Minute>27</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2021</Year>
          <Month>12</Month>
          <Day>14</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>24</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">34894987</ArticleId>
        <ArticleId IdType="pmc">PMC8667948</ArticleId>
        <ArticleId IdType="doi">10.1080/14756366.2021.1994558</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Organization WH . Global antimicrobial resistance surveillance system (glass) report: early implementation 2020. In. Global antimicrobial resistance surveillance system (glass) report: early implementation 2020; Geneva; 2020.</Citation>
        </Reference>
        <Reference>
          <Citation>CDC . Antibiotic resistance threats in the United States. In: Antibiotic resistance threats in the United States. Atlanta (GA): U.S. Department of Health and Human Services; 2019.</Citation>
        </Reference>
        <Reference>
          <Citation>CDC . Antibiotic resistance threats in the United States, 2013. In: Antibiotic resistance threats in the United States. Atlanta (GA): U.S. Centers for Disease Control and Prevention; 2013.</Citation>
        </Reference>
        <Reference>
          <Citation>Cassini A, Högberg LD, Plachouras D, et al. . 
Attributable deaths and disability-adjusted life-years caused by infections with antibiotic-resistant bacteria in the eu and the European economic area in 2015: a population-level modelling analysis. Lancet Infect Dis
2019;19:56–66.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6300481</ArticleId>
            <ArticleId IdType="pubmed">30409683</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Renner LD, Zan J, Hu LI, et al. . 
Detection of eskape bacterial pathogens at the point of care using isothermal DNA-based assays in a portable degas-actuated microfluidic diagnostic assay platform. Appl Environ Microbiol
2017;83:e02449–02416.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5288812</ArticleId>
            <ArticleId IdType="pubmed">27986722</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pendleton JN, Gorman SP, Gilmore BF.. 
Clinical relevance of the eskape pathogens. Expert Rev Anti Infect Ther
2013;11:297–308.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23458769</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rice LB.
Federal funding for the study of antimicrobial resistance in nosocomial pathogens: no eskape. J Infect Dis
2008:197:1079–81.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18419525</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Santajit S, Indrawattana N.. 
Mechanisms of antimicrobial resistance in eskape pathogens. BioMed Res Int
2016:2016:2475067.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4871955</ArticleId>
            <ArticleId IdType="pubmed">27274985</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Delcour AH.
Outer membrane permeability and antibiotic resistance. Biochimica et biophysica acta
2009:1794:808–16.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2696358</ArticleId>
            <ArticleId IdType="pubmed">19100346</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Miller SI.
Antibiotic resistance and regulation of the gram-negative bacterial outer membrane barrier by host innate immune molecules. mBio
2016;7:e01541–01516.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5040116</ArticleId>
            <ArticleId IdType="pubmed">27677793</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Breijyeh Z, Jubeh B, Karaman R.. 
Resistance of gram-negative bacteria to current antibacterial agents and approaches to resolve it. Molecules
2020;25:1340.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7144564</ArticleId>
            <ArticleId IdType="pubmed">32187986</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Aslam B, Wang W, Arshad MI, et al. . 
Antibiotic resistance: a rundown of a global crisis. Infect drug Resist
2018:11;1645–58.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6188119</ArticleId>
            <ArticleId IdType="pubmed">30349322</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Coates ARM, Halls G, Hu Y.. 
Novel classes of antibiotics or more of the same?
Br J Pharmacol
2011:163:184–94.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3085877</ArticleId>
            <ArticleId IdType="pubmed">21323894</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Infectious Diseases Society of A . The 10 × 20 initiative: pursuing a global commitment to develop 10 new antibacterial drugs by 2020. Clin Infect Dis
2010;50:1081–83.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20214473</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Talbot GH, Jezek A, Murray BE, et al. . 
The infectious diseases society of America’s 10 × ‘20 initiative (10 new systemic antibacterial agents us food and drug administration approved by 2020): is 20 × 20 a possibility?
Clin Infect Dis
2019;69:1–11.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30715222</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yao J, Rock CO.. 
How bacterial pathogens eat host lipids: implications for the development of fatty acid synthesis therapeutics. J Biol Chem
2015:290:5940–5946.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4358231</ArticleId>
            <ArticleId IdType="pubmed">25648887</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Parsons JB, Rock CO.. 
Is bacterial fatty acid synthesis a valid target for antibacterial drug discovery?
Curr Opin Microbiol
2011;14:544–49.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3193581</ArticleId>
            <ArticleId IdType="pubmed">21862391</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Turner KH, Wessel AK, Palmer GC, et al. . 
Essential genome of pseudomonas aeruginosa in cystic fibrosis sputum. Proc Natl Acad Sci USA
2015:112:4110–15.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4386324</ArticleId>
            <ArticleId IdType="pubmed">25775563</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Parsons JB, Frank MW, Subramanian C, et al. . 
Metabolic basis for the differential susceptibility of gram-positive pathogens to fatty acid synthesis inhibitors. Proc Natl Acad Sci USA
2011:108:15378–83.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3174620</ArticleId>
            <ArticleId IdType="pubmed">21876172</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Raetz CRH, Reynolds CM, Trent MS, Bishop RE.. 
Lipid a modification systems in gram-negative bacteria. Ann Rev Biochem
2007;76:295–329.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2569861</ArticleId>
            <ArticleId IdType="pubmed">17362200</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Parsons JB, Rock CO.. 
Bacterial lipids: metabolism and membrane homeostasis. Prog Lipid Res
2013;52:249–76.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3665635</ArticleId>
            <ArticleId IdType="pubmed">23500459</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cronan JE, Waldrop GL.. 
Multi-subunit acetyl-coa carboxylases. Prog Lipid Res
2002;41:407–35.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12121720</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Campbell JW, John E.Cronan J.. 
Bacterial fatty acid biosynthesis: targets for antibacterial drug discovery. Ann Rev Microbiol
2001;55:305–32.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11544358</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Freiberg C, Brunner NA, Schiffer G, et al. . 
Identification and characterization of the first class of potent bacterial acetyl-coa carboxylase inhibitors with antibacterial activity. J Biol Chem
2004:279:26066–73.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15066985</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mochalkin I, Miller JR, Narasimhan L, et al. . 
Discovery of antibacterial biotin carboxylase inhibitors by virtual screening and fragment-based approaches. ACS Chem Biol
2009;4:473–83.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19413326</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cheng CC, Shipps GW, Yang Z, et al. . 
Discovery and optimization of antibacterial accc inhibitors. Bioorg Med Chem Lett
2009;19:6507–14.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19875284</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Miller JR, Dunham S, Mochalkin I, et al. . 
A class of selective antibacterials derived from a protein kinase inhibitor pharmacophore. Proc Natl Acad Sci USA
2009:106:1737–42.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2644107</ArticleId>
            <ArticleId IdType="pubmed">19164768</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wallace J, Bowlin NO, Mills DM, et al. . 
Discovery of bacterial fatty acid synthase type II inhibitors using a novel cellular bioluminescent reporter assay. Antimicrob Agents Chemother
2015;59:5775–87.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4538483</ArticleId>
            <ArticleId IdType="pubmed">26169404</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Blanchard CZ, Lee YM, Frantom PA, Waldrop GL.. 
Mutations at four active site residues of biotin carboxylase abolish substrate-induced synergism by biotin. Biochemistry
1999;38:3393–400.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10079084</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Broussard TC, Price AE, Laborde SM, Waldrop GL.. 
Complex formation and regulation of Escherichia coli acetyl-coa carboxylase. Biochemistry
2013;52:3346–57.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23594205</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Blanchard CZ, Waldrop GL.. 
Overexpression and kinetic characterization of the carboxyltransferase component of acetyl-coa carboxylase. J Biol Chem
1998:273:19140–45.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9668099</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Webb MR.
A continuous spectrophotometric assay for inorganic phosphate and for measuring phosphate release kinetics in biological systems. Proc Natl Acad Sci USA
1992;89:4884–87.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC49192</ArticleId>
            <ArticleId IdType="pubmed">1534409</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cleland WW.
Statistical analysis of enzyme kinetic data. Methods Enzymol
1979:63;103–38.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">502857</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Leatherbarrow RJ. Enzfitter: a non-linear regression data analysis program for the IBM PC and true compatibles; manuel. Biosoft 1987.</Citation>
        </Reference>
        <Reference>
          <Citation>Sterling T, Irwin JJ.. 
Zinc 15-ligand discovery for everyone. J Chem Inform Model
2015;55:2324–37.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4658288</ArticleId>
            <ArticleId IdType="pubmed">26479676</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Morris GM, Huey R, Lindstrom W, et al. . 
Autodock4 and autodocktools4: automated docking with selective receptor flexibility. J Comput Chem
2009;30:2785–91.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2760638</ArticleId>
            <ArticleId IdType="pubmed">19399780</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Feinstein WP, Brylinski M.. 
Calculating an optimal box size for ligand docking and virtual screening against experimental and predicted binding pockets. J Cheminform
2015;7:18.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4468813</ArticleId>
            <ArticleId IdType="pubmed">26082804</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Broussard TC, Pakhomova S, Neau DB, et al. . 
Structural analysis of substrate, reaction intermediate, and product binding in haemophilus influenzae biotin carboxylase. Biochemistry
2015;54:3860–70.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4654113</ArticleId>
            <ArticleId IdType="pubmed">26020841</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Trott O, Olson AJ.. 
Autodock vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J Comput Chem
2010;31:455–61.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3041641</ArticleId>
            <ArticleId IdType="pubmed">19499576</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>O’Boyle NM, Banck M, James CA, et al. . 
Open babel: an open chemical toolbox. J Cheminformatics
2011;3:33.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3198950</ArticleId>
            <ArticleId IdType="pubmed">21982300</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schrodinger, LLC. The pymol molecular graphics system, version 1.8. In: The pymol molecular graphics system, version 1.8; November; 2015.</Citation>
        </Reference>
        <Reference>
          <Citation>Yonetani T, Theorell H.. 
Studies on liver alcohol hydrogenase complexes. 3. Multiple inhibition kinetics in the presence of two competitive inhibitors. Arch Biochem Biophys
1964:106;243–51.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">14217165</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dimroth P, Guchhait RB, Stoll E, Lane MD.. 
Enzymatic carboxylation of biotin: molecular and catalytic properties of a component enzyme of acetyl coa carboxylase. Proc Natl Acad Sci
1970;67:1353–60.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC283359</ArticleId>
            <ArticleId IdType="pubmed">4922289</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cleland WW.
Determining the chemical mechanisms of enzyme-catalyzed reactions by kinetic studies. Adv Enzymol Relat Areas Mol Biol
1977:45;273–387.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21524</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tipton PA, Cleland WW.. 
Catalytic mechanism of biotin carboxylase: steady-state kinetic investigations. Biochemistry
1988;27:4317–25.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">2971391</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Weeks G, Wakil SJ.. 
Studies on the mechanism of fatty acid synthesis: xviii. Preparation and general properties of the enoyl acyl carrier protein reductases from Escherichia coli. J Biol Chem
1968:243:1180–9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">4384650</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Quemard A, Sacchettini JC, Dessen A, et al. . 
Enzymic characterization of the target for isoniazid in mycobacterium tuberculosis. Biochemistry
1995;34:8235–41.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">7599116</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ward WHJ, Holdgate GA, Rowsell S, et al. . 
Kinetic and structural characteristics of the inhibition of enoyl (acyl carrier protein) reductase by triclosan. Biochemistry
1999;38:12514–25.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10493822</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Heath RJ, Rubin JR, Holland DR, et al. . 
Mechanism of triclosan inhibition of bacterial fatty acid synthesis*. J Biol Chem
1999:274:11110–14.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10196195</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Silvers MA, Robertson GT, Taylor CM, Waldrop GL.. 
Design, synthesis, and antibacterial properties of dual-ligand inhibitors of acetyl-coa carboxylase. J Med Chem
2014;57:8947–59.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25280369</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vasiliou V, Vasiliou K, Nebert DW.. 
Human ATP-binding cassette (abc) transporter family. Hum Genomics
2009;3:281–290.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2752038</ArticleId>
            <ArticleId IdType="pubmed">19403462</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Umate P, Tuteja N, Tuteja R.. 
Genome-wide comprehensive analysis of human helicases. Commun Integr Biol
2011;4:118–137.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3073292</ArticleId>
            <ArticleId IdType="pubmed">21509200</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Duong-Ly KC, Peterson JR.. 
The human kinome and kinase inhibition. Curr Protocols Pharmacol, 2013;Unit2.9:60.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4128285</ArticleId>
            <ArticleId IdType="pubmed">23456613</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sloane V, Waldrop GL.. 
Kinetic characterization of mutations found in propionic acidemia and methylcrotonylglycinuria: evidence for cooperativity in biotin carboxylase. J Biol Chem
2004:279:15772–78.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">14960587</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tong L.
Structure and function of biotin-dependent carboxylases. Cell Mol Life Sci
2013;70:863–91.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3508090</ArticleId>
            <ArticleId IdType="pubmed">22869039</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">34894987</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>02</Month>
        <Day>23</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>02</Month>
        <Day>23</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Electronic">1475-6374</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>37</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Dec</Month>
            </PubDate>
          </JournalIssue>
          <Title>Journal of enzyme inhibition and medicinal chemistry</Title>
          <ISOAbbreviation>J Enzyme Inhib Med Chem</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Mechanism of biotin carboxylase inhibition by ethyl 4-[[2-chloro-5-(phenylcarbamoyl)phenyl]sulphonylamino]benzoate.</ArticleTitle>
        <Pagination>
          <StartPage>100</StartPage>
          <EndPage>108</EndPage>
          <MedlinePgn>100-108</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1080/14756366.2021.1994558</ELocationID>
        <Abstract>
          <AbstractText>The rise of antibacterial-resistant bacteria is a major problem in the United States of America and around the world. Millions of patients are infected with antimicrobial resistant bacteria each year. Novel antibacterial agents are needed to combat the growing and present crisis. Acetyl-CoA carboxylase (ACC), the multi-subunit complex which catalyses the first committed step in fatty acid synthesis, is a validated target for antibacterial agents. However, there are at present, no commercially available antibiotics that target ACC. Ethyl 4-[[2-chloro-5-(phenylcarbamoyl)phenyl]sulfonylamino]benzoate (SABA1) is a compound that has been shown to have antibacterial properties against <i>Pseudomonas aeruginosa</i> and <i>Escherichia coli</i>. SABA1 inhibits biotin carboxylase (BC), the enzyme that catalyses the first half reaction of ACC. SABA1 inhibits BC via an atypical mechanism. It binds in the biotin binding site in the presence of ADP. SABA1 represents a potentially new class of antibiotics that can be used to combat the antibacterial resistance crisis.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Craft</LastName>
            <ForeName>Matthew K</ForeName>
            <Initials>MK</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Biological Sciences, Louisiana State University, Baton Rouge, LA, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Waldrop</LastName>
            <ForeName>Grover L</ForeName>
            <Initials>GL</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Biological Sciences, Louisiana State University, Baton Rouge, LA, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>J Enzyme Inhib Med Chem</MedlineTA>
        <NlmUniqueID>101150203</NlmUniqueID>
        <ISSNLinking>1475-6366</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000900">Anti-Bacterial Agents</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D004791">Enzyme Inhibitors</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 6.3.-</RegistryNumber>
          <NameOfSubstance UI="D019731">Carbon-Nitrogen Ligases</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 6.3.4.14</RegistryNumber>
          <NameOfSubstance UI="C019791">biotin carboxylase</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000900" MajorTopicYN="N">Anti-Bacterial Agents</DescriptorName>
          <QualifierName UI="Q000138" MajorTopicYN="N">chemical synthesis</QualifierName>
          <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019731" MajorTopicYN="N">Carbon-Nitrogen Ligases</DescriptorName>
          <QualifierName UI="Q000037" MajorTopicYN="Y">antagonists &amp; inhibitors</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004305" MajorTopicYN="N">Dose-Response Relationship, Drug</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004791" MajorTopicYN="N">Enzyme Inhibitors</DescriptorName>
          <QualifierName UI="Q000138" MajorTopicYN="N">chemical synthesis</QualifierName>
          <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004926" MajorTopicYN="N">Escherichia coli</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008826" MajorTopicYN="N">Microbial Sensitivity Tests</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015394" MajorTopicYN="N">Molecular Structure</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011550" MajorTopicYN="N">Pseudomonas aeruginosa</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013329" MajorTopicYN="N">Structure-Activity Relationship</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Antibiotics</Keyword>
        <Keyword MajorTopicYN="N">acetyl-CoA carboxylase</Keyword>
        <Keyword MajorTopicYN="N">fatty acid synthesis</Keyword>
        <Keyword MajorTopicYN="N">molecular docking</Keyword>
      </KeywordList>
      <CoiStatement>No potential conflict of interest was reported by the author(s).</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="entrez">
          <Year>2021</Year>
          <Month>12</Month>
          <Day>13</Day>
          <Hour>11</Hour>
          <Minute>27</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2021</Year>
          <Month>12</Month>
          <Day>14</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>24</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">34894987</ArticleId>
        <ArticleId IdType="pmc">PMC8667948</ArticleId>
        <ArticleId IdType="doi">10.1080/14756366.2021.1994558</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Organization WH . Global antimicrobial resistance surveillance system (glass) report: early implementation 2020. In. Global antimicrobial resistance surveillance system (glass) report: early implementation 2020; Geneva; 2020.</Citation>
        </Reference>
        <Reference>
          <Citation>CDC . Antibiotic resistance threats in the United States. In: Antibiotic resistance threats in the United States. Atlanta (GA): U.S. Department of Health and Human Services; 2019.</Citation>
        </Reference>
        <Reference>
          <Citation>CDC . Antibiotic resistance threats in the United States, 2013. In: Antibiotic resistance threats in the United States. Atlanta (GA): U.S. Centers for Disease Control and Prevention; 2013.</Citation>
        </Reference>
        <Reference>
          <Citation>Cassini A, Högberg LD, Plachouras D, et al. . 
Attributable deaths and disability-adjusted life-years caused by infections with antibiotic-resistant bacteria in the eu and the European economic area in 2015: a population-level modelling analysis. Lancet Infect Dis
2019;19:56–66.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6300481</ArticleId>
            <ArticleId IdType="pubmed">30409683</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Renner LD, Zan J, Hu LI, et al. . 
Detection of eskape bacterial pathogens at the point of care using isothermal DNA-based assays in a portable degas-actuated microfluidic diagnostic assay platform. Appl Environ Microbiol
2017;83:e02449–02416.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5288812</ArticleId>
            <ArticleId IdType="pubmed">27986722</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pendleton JN, Gorman SP, Gilmore BF.. 
Clinical relevance of the eskape pathogens. Expert Rev Anti Infect Ther
2013;11:297–308.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23458769</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rice LB.
Federal funding for the study of antimicrobial resistance in nosocomial pathogens: no eskape. J Infect Dis
2008:197:1079–81.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18419525</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Santajit S, Indrawattana N.. 
Mechanisms of antimicrobial resistance in eskape pathogens. BioMed Res Int
2016:2016:2475067.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4871955</ArticleId>
            <ArticleId IdType="pubmed">27274985</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Delcour AH.
Outer membrane permeability and antibiotic resistance. Biochimica et biophysica acta
2009:1794:808–16.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2696358</ArticleId>
            <ArticleId IdType="pubmed">19100346</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Miller SI.
Antibiotic resistance and regulation of the gram-negative bacterial outer membrane barrier by host innate immune molecules. mBio
2016;7:e01541–01516.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5040116</ArticleId>
            <ArticleId IdType="pubmed">27677793</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Breijyeh Z, Jubeh B, Karaman R.. 
Resistance of gram-negative bacteria to current antibacterial agents and approaches to resolve it. Molecules
2020;25:1340.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7144564</ArticleId>
            <ArticleId IdType="pubmed">32187986</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Aslam B, Wang W, Arshad MI, et al. . 
Antibiotic resistance: a rundown of a global crisis. Infect drug Resist
2018:11;1645–58.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6188119</ArticleId>
            <ArticleId IdType="pubmed">30349322</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Coates ARM, Halls G, Hu Y.. 
Novel classes of antibiotics or more of the same?
Br J Pharmacol
2011:163:184–94.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3085877</ArticleId>
            <ArticleId IdType="pubmed">21323894</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Infectious Diseases Society of A . The 10 × 20 initiative: pursuing a global commitment to develop 10 new antibacterial drugs by 2020. Clin Infect Dis
2010;50:1081–83.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20214473</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Talbot GH, Jezek A, Murray BE, et al. . 
The infectious diseases society of America’s 10 × ‘20 initiative (10 new systemic antibacterial agents us food and drug administration approved by 2020): is 20 × 20 a possibility?
Clin Infect Dis
2019;69:1–11.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30715222</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yao J, Rock CO.. 
How bacterial pathogens eat host lipids: implications for the development of fatty acid synthesis therapeutics. J Biol Chem
2015:290:5940–5946.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4358231</ArticleId>
            <ArticleId IdType="pubmed">25648887</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Parsons JB, Rock CO.. 
Is bacterial fatty acid synthesis a valid target for antibacterial drug discovery?
Curr Opin Microbiol
2011;14:544–49.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3193581</ArticleId>
            <ArticleId IdType="pubmed">21862391</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Turner KH, Wessel AK, Palmer GC, et al. . 
Essential genome of pseudomonas aeruginosa in cystic fibrosis sputum. Proc Natl Acad Sci USA
2015:112:4110–15.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4386324</ArticleId>
            <ArticleId IdType="pubmed">25775563</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Parsons JB, Frank MW, Subramanian C, et al. . 
Metabolic basis for the differential susceptibility of gram-positive pathogens to fatty acid synthesis inhibitors. Proc Natl Acad Sci USA
2011:108:15378–83.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3174620</ArticleId>
            <ArticleId IdType="pubmed">21876172</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Raetz CRH, Reynolds CM, Trent MS, Bishop RE.. 
Lipid a modification systems in gram-negative bacteria. Ann Rev Biochem
2007;76:295–329.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2569861</ArticleId>
            <ArticleId IdType="pubmed">17362200</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Parsons JB, Rock CO.. 
Bacterial lipids: metabolism and membrane homeostasis. Prog Lipid Res
2013;52:249–76.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3665635</ArticleId>
            <ArticleId IdType="pubmed">23500459</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cronan JE, Waldrop GL.. 
Multi-subunit acetyl-coa carboxylases. Prog Lipid Res
2002;41:407–35.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12121720</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Campbell JW, John E.Cronan J.. 
Bacterial fatty acid biosynthesis: targets for antibacterial drug discovery. Ann Rev Microbiol
2001;55:305–32.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11544358</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Freiberg C, Brunner NA, Schiffer G, et al. . 
Identification and characterization of the first class of potent bacterial acetyl-coa carboxylase inhibitors with antibacterial activity. J Biol Chem
2004:279:26066–73.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15066985</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mochalkin I, Miller JR, Narasimhan L, et al. . 
Discovery of antibacterial biotin carboxylase inhibitors by virtual screening and fragment-based approaches. ACS Chem Biol
2009;4:473–83.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19413326</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cheng CC, Shipps GW, Yang Z, et al. . 
Discovery and optimization of antibacterial accc inhibitors. Bioorg Med Chem Lett
2009;19:6507–14.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19875284</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Miller JR, Dunham S, Mochalkin I, et al. . 
A class of selective antibacterials derived from a protein kinase inhibitor pharmacophore. Proc Natl Acad Sci USA
2009:106:1737–42.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2644107</ArticleId>
            <ArticleId IdType="pubmed">19164768</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wallace J, Bowlin NO, Mills DM, et al. . 
Discovery of bacterial fatty acid synthase type II inhibitors using a novel cellular bioluminescent reporter assay. Antimicrob Agents Chemother
2015;59:5775–87.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4538483</ArticleId>
            <ArticleId IdType="pubmed">26169404</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Blanchard CZ, Lee YM, Frantom PA, Waldrop GL.. 
Mutations at four active site residues of biotin carboxylase abolish substrate-induced synergism by biotin. Biochemistry
1999;38:3393–400.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10079084</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Broussard TC, Price AE, Laborde SM, Waldrop GL.. 
Complex formation and regulation of Escherichia coli acetyl-coa carboxylase. Biochemistry
2013;52:3346–57.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23594205</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Blanchard CZ, Waldrop GL.. 
Overexpression and kinetic characterization of the carboxyltransferase component of acetyl-coa carboxylase. J Biol Chem
1998:273:19140–45.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9668099</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Webb MR.
A continuous spectrophotometric assay for inorganic phosphate and for measuring phosphate release kinetics in biological systems. Proc Natl Acad Sci USA
1992;89:4884–87.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC49192</ArticleId>
            <ArticleId IdType="pubmed">1534409</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cleland WW.
Statistical analysis of enzyme kinetic data. Methods Enzymol
1979:63;103–38.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">502857</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Leatherbarrow RJ. Enzfitter: a non-linear regression data analysis program for the IBM PC and true compatibles; manuel. Biosoft 1987.</Citation>
        </Reference>
        <Reference>
          <Citation>Sterling T, Irwin JJ.. 
Zinc 15-ligand discovery for everyone. J Chem Inform Model
2015;55:2324–37.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4658288</ArticleId>
            <ArticleId IdType="pubmed">26479676</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Morris GM, Huey R, Lindstrom W, et al. . 
Autodock4 and autodocktools4: automated docking with selective receptor flexibility. J Comput Chem
2009;30:2785–91.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2760638</ArticleId>
            <ArticleId IdType="pubmed">19399780</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Feinstein WP, Brylinski M.. 
Calculating an optimal box size for ligand docking and virtual screening against experimental and predicted binding pockets. J Cheminform
2015;7:18.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4468813</ArticleId>
            <ArticleId IdType="pubmed">26082804</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Broussard TC, Pakhomova S, Neau DB, et al. . 
Structural analysis of substrate, reaction intermediate, and product binding in haemophilus influenzae biotin carboxylase. Biochemistry
2015;54:3860–70.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4654113</ArticleId>
            <ArticleId IdType="pubmed">26020841</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Trott O, Olson AJ.. 
Autodock vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J Comput Chem
2010;31:455–61.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3041641</ArticleId>
            <ArticleId IdType="pubmed">19499576</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>O’Boyle NM, Banck M, James CA, et al. . 
Open babel: an open chemical toolbox. J Cheminformatics
2011;3:33.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3198950</ArticleId>
            <ArticleId IdType="pubmed">21982300</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schrodinger, LLC. The pymol molecular graphics system, version 1.8. In: The pymol molecular graphics system, version 1.8; November; 2015.</Citation>
        </Reference>
        <Reference>
          <Citation>Yonetani T, Theorell H.. 
Studies on liver alcohol hydrogenase complexes. 3. Multiple inhibition kinetics in the presence of two competitive inhibitors. Arch Biochem Biophys
1964:106;243–51.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">14217165</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dimroth P, Guchhait RB, Stoll E, Lane MD.. 
Enzymatic carboxylation of biotin: molecular and catalytic properties of a component enzyme of acetyl coa carboxylase. Proc Natl Acad Sci
1970;67:1353–60.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC283359</ArticleId>
            <ArticleId IdType="pubmed">4922289</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cleland WW.
Determining the chemical mechanisms of enzyme-catalyzed reactions by kinetic studies. Adv Enzymol Relat Areas Mol Biol
1977:45;273–387.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21524</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tipton PA, Cleland WW.. 
Catalytic mechanism of biotin carboxylase: steady-state kinetic investigations. Biochemistry
1988;27:4317–25.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">2971391</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Weeks G, Wakil SJ.. 
Studies on the mechanism of fatty acid synthesis: xviii. Preparation and general properties of the enoyl acyl carrier protein reductases from Escherichia coli. J Biol Chem
1968:243:1180–9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">4384650</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Quemard A, Sacchettini JC, Dessen A, et al. . 
Enzymic characterization of the target for isoniazid in mycobacterium tuberculosis. Biochemistry
1995;34:8235–41.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">7599116</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ward WHJ, Holdgate GA, Rowsell S, et al. . 
Kinetic and structural characteristics of the inhibition of enoyl (acyl carrier protein) reductase by triclosan. Biochemistry
1999;38:12514–25.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10493822</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Heath RJ, Rubin JR, Holland DR, et al. . 
Mechanism of triclosan inhibition of bacterial fatty acid synthesis*. J Biol Chem
1999:274:11110–14.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10196195</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Silvers MA, Robertson GT, Taylor CM, Waldrop GL.. 
Design, synthesis, and antibacterial properties of dual-ligand inhibitors of acetyl-coa carboxylase. J Med Chem
2014;57:8947–59.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25280369</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vasiliou V, Vasiliou K, Nebert DW.. 
Human ATP-binding cassette (abc) transporter family. Hum Genomics
2009;3:281–290.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2752038</ArticleId>
            <ArticleId IdType="pubmed">19403462</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Umate P, Tuteja N, Tuteja R.. 
Genome-wide comprehensive analysis of human helicases. Commun Integr Biol
2011;4:118–137.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3073292</ArticleId>
            <ArticleId IdType="pubmed">21509200</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Duong-Ly KC, Peterson JR.. 
The human kinome and kinase inhibition. Curr Protocols Pharmacol, 2013;Unit2.9:60.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4128285</ArticleId>
            <ArticleId IdType="pubmed">23456613</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sloane V, Waldrop GL.. 
Kinetic characterization of mutations found in propionic acidemia and methylcrotonylglycinuria: evidence for cooperativity in biotin carboxylase. J Biol Chem
2004:279:15772–78.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">14960587</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tong L.
Structure and function of biotin-dependent carboxylases. Cell Mol Life Sci
2013;70:863–91.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3508090</ArticleId>
            <ArticleId IdType="pubmed">22869039</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
